trend in innovation finance in the eu marc schublin, head of division, european investment fund
DESCRIPTION
TREND IN INNOVATION FINANCE IN THE EU Marc Schublin, Head of Division, European Investment Fund Coordination – General Affairs – Advisory Services Knowledge Economy Forum IV, Istanbul, 23 March 2005. Finance for innovation = the EU side. Summary. EIF as EU Fund of Funds - PowerPoint PPT PresentationTRANSCRIPT
TREND IN INNOVATION FINANCE IN THE EUMarc Schublin, Head of Division,
European Investment FundCoordination – General Affairs – Advisory Services
Knowledge Economy Forum IV, Istanbul, 23 March 2005
2
Finance for innovation = the EU side
EIF as EU Fund of Funds
Venture Capital: a difficult market
The limits of Venture Capital in supporting innovation
New Initiatives throughout the EU
Towards new financial instruments and concepts
Summary
3
EIF at a glance
Institutional set-up : Shareholders: European
Investment Bank (60%) – European Commission (30%) – 31 banks 10%)
Contribute to Community objectives (entrepreneurship, research and innovation, regional development, etc …)
Ensure an appropriate return on its own resources
Important role in the context of Lisbon Strategy / 3% target (Innovation – Employment)
EIF products – Venture capital / “Risk Capital Arm” of EIB
SME Portfolio guarantees
… and Advisory services / Technical assistance
4
VC investments: EIF’s role
Biggest European early-stage Fund of Funds (EUR 3bn in 200 Funds)
Participates as a pari-passu cornerstone investor (always commercial terms)
Long-term committed and pro-active investor
Know-how helps in structuring a fund / best practice
Widespread network in European venture capital industry which may help to attract co-investors
Neutral, supranational investor
Investments based on own resources and mainly on behalf of EIB VC mandate, EC Seed Capital scheme and ERP Facility (early stage in Germany)
Investment activity only in EU and Acceding Countries
5
The innovation cycle covered by EIF
Future coverage
Later-stage
Buy-out
IPOs
Tech
Transfer
Incubators
Pre-Seed
Business
Angels
Expansion /
Dev.
Capital
Early StageSeed
* Currently covered by EIF advisory services (Technology Transfer Accelerator)
ADVISORY
« VENTURE CAPITAL » « PRIVATE EQUITY »
Future extended coverage *
6
0
50
100
150
200
250
300
350
400
450
1990
1992
1994
1996
1998
2000
2002
No
. fir
ms/
fun
ds
0.00
5,000.00
10,000.00
15,000.00
20,000.00
25,000.00
30,000.00
35,000.00
40,000.00
US
D m
illio
ns
No. Firms
No. Funds
Sum cap (USD millions)
European VC Funds Raised 1990 to 2003: few investors stay on board
Source: EVCA / Thomson Financial / PricewaterhouseCoopers
7
VC is a Risky Business
Pooled IRR - December 31, 2003:
Early stage : 1.9% (Top Quarter: 14.8%)
All Venture : 7.2% (Top Quarter: 23.9%)
best performing funds are in the segment of €100-250m = 9.2% or 12.8% over a 10-year period
All Private Equity : 9.9% (Top Quarter: 24.3%)
Source: European Venture Capital Association (EVCA)
8
Constraints and limits of VC in supporting Innovation
High risk; very qualified management teams needed
Balance public/private investors?
Good VC funds governance (independence of managers vs investors, transparence, etc.)
Management costs, long maturity
Critical mass
Seed-early stage especially efficient near important “technological clusters” (Heidelberg, Cambridge, Finland, etc…)
In the EU, about 15 000 companies supported by VC (compared to a total SME population of 14 million)
9
Constraints and limits of VC in support of Innovation: some lessons learnt
Mainly recent public initiatives through appropriate use of budget funding (Research, SME)
Critical mass, grouping of energies, system approach necessary (national vs regional?)
Legal, tax issues are key (No European patent!)
10
How to support seed? Interesting initiatives (private, public, financial, political)
IP2IPO (UK) = example GBP 20m loan to Oxford Chemistry Department repaid through 50% of IPR during 15 years
KAROLINSKA (S) = pooling of spin-offs sold to VCs
France = merger of Public Innovation Agency ANVAR (managing grants) and SME Development Bank
creation of “pôles technologiques” (super clusters)
+ UK, B, NL, ITA, etc Appropriation of “Lisbon Strategy” by EU Member States
11
EIF’s role in this context
Be proactive (EU summit 23 March 2005) on the investment side =
1. Side funds with Business Angels (BA) (if structured as BA networks) (Specific EU funding under the Competitiveness & Innovation Programme)
2. Common approach with EIB, generation of hybrid instruments (Loan – Equity – Mezzanine)
Develop Advisory Services and Technical Assistance
12
Advisory Services
Complement the 2 main product lines, EIF as a “Multilateral Development Bank” committed to provide technical assistance and advisory services
Objective is to provide financial engineering to organisations active in the field of VC and SME Guarantees
Fee based activity
Two domains of intervention
Creation, growth and development of SMEs VC, seed capital, guarantee schemes, business angel networks, tech transfer, etc. for
regional and national authorities / Agencies
Complex financial structures: for the European Commission
13
Advisory Services
TTA : Avoid fragmentation, incentive Research Centres to work together, bridge the gap between Research and Market
CDTI project : public Innovation Fund of Funds, with targeted support to Tech SMEs (Spain)
14
TTA 1
Cluster Size
Cambridge UK
Munich Boston
Researchers 23,5509,200 6,300
Publications 38,000
15,000 10,000
Number of public companies created
>38>11 >4
Number of biotechcompanies located in cluster
>200>110 >60
Bay Area
N/A
29,500
>44
>190
Large clusters necessary to build self-sustaining ecosystem
Source: European Innovation Scoreboard, BCG Cluster Report 2001, EIF analysis and interviews
15
TTA 1
Licensing Revenues2002
Licensing activity too small to create
any noticeable effects
US Europe
University Revenues [m€] University Revenues [m€]
Columbia Univeristy 115.4
65.3Stanford University 50.0University of New York 49.9
43.3University of Rochester 33.5
31.4MIT 30.2
25.6Florida University 25.2
University of California
City of Hope National
University of Wisconsin-Madison
Sloan Kettering Institute for Cancer Research
Pasteur 32.6
University of Edinburgh 4.5
Utrecht* 4.0
Cambridge 3.1
INRIA* 3.0
VIB* 2.7
LMU Munich 0.2
Note: *Includes other forms of revenuesSource: European Innovation Scoreboard, BCG Cluster Report 2001, EIF analysis and interviews
16
TTA 2: Focus of TTA funding: Types of SPVs funded by the TTA
R&DTech transfer / Proof-of-concept
Marketable product
«Techno-logy» IP
«Prototype » IP
LAB
« Licensing » SPVs
« Spin off » SPVs
« Hybrid » SPVs
Licensing to corporation
Sale to corporation
Purchase / investment by other investors
IPO
Potential exits for the SPV projects
Investment focus of TTA
17
CDTI 1
Fund of
Funds
Parallel supplementary
vehicle
The CDTI/EIF Spanish Venture Capital Investment Programme
EIF Programme
Manager/Advisor
CDTI
Programme
technology partnerYoung Fund
Window
Generalist
fundsTech /
Innovation funds
Foreign
tech funds
Tech SMEs Generalist SMEs Tech SMEs Tech SMEs Tech SMEs
Co-invests 1:1